AK112-301-HARMONi

To compare overall survival (OS) in the Modified Intent-to-Treat (mITT) population;between AK112 combined with pemetrexed and carboplatin and placebo combined;with pemetrexed and carboplatin, in patients with locally advanced or metastatic nonsquamous;non-small cell lung cancer (NSCLC) with epidermal growth factor receptor;(EGFR) mutations who have progressed on or following EGFR tyrosine kinase;inhibitor (TKI) therapy.;À To compare progression-free survival (PFS) assessed by the Independent Radiology;Review Committee (IRRC) based on Response Evaluation Criteria in Solid Tumors;(RECIST) v1.1, in the mITT population between AK112 combined with pemetrexed;and carboplatin and placebo combined with pemetrexed and carboplatin, in patients;with locally advanced or metastatic non-squamous NSCLC with EGFR mutations who;have progressed on or following EGFR TKI therapy